ERBB2 and cancer: FS-1502 is a HER2-targeting ADC comprising a cancer-selective cleavable β-glucuronide linker, an anti-HER2 antibody derived from trastuzumab, and an antimitotic agent, monomethyl auristatin F (MMAF), which inhibits tubulin polymerization.